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Background: Vitamin D deficiency has been implicated as a factor in a number of infectious and inflammatory
lung diseases. In the lung, alveolar macrophages play a key role in inflammation and defense of infection, but there
are little data exploring the immunomodulatory effects of vitamin D on innate lung immunity in humans. The
objective of this study was to determine the effects of vitamin D supplementation on gene expression of alveolar
macrophages.
Methods: We performed a parallel, double-blind, placebo-controlled, randomized trial to determine the effects of
vitamin D on alveolar macrophage gene expression. Vitamin D3 (1000 international units/day) or placebo was
administered to adults for three months. Bronchoscopy was performed pre- and post-intervention to obtain alveolar
macrophages. Messenger RNA was isolated from the macrophages and subjected to whole genome exon array
analysis. The primary outcome was differential gene expression of the alveolar macrophage in response to vitamin
D supplementation. Specific genes underwent validation by polymerase chain reaction methods.
Results: Fifty-eight subjects were randomized to vitamin D (n = 28) or placebo (n = 30). There was a marginal
overall difference between treatment group and placebo group in the change of 25-hydroxyvitaminD levels
(4.43 ng/ml vs. 0.2 ng/ml, p = 0.10). Whole genome exon array analysis revealed differential gene expression
associated with change in serum vitamin D levels in the treated group. CCL8/MCP-2 was the top-regulated cytokine
gene and was further validated.
Conclusions: Although only a non-significant increased trend was seen in serum vitamin D levels, subjects treated
with vitamin D supplementation had immune-related differential gene expression in alveolar macrophages.
Trial registration: ClinicalTrials.org: NCT01967628.
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Vitamin D is suspected to be an important factor in sus-
ceptibility to bacterial and viral infections of the lung
[1]. Historically, Vitamin D has been used as a treatment
for tuberculosis [2]. More recently, deficiency has been
associated with influenza, increased severity of community
acquired pneumonia and development of chronic ob-
structive pulmonary disease (COPD) [3-5]. The mechanisms* Correspondence: alicia-gerke@uiowa.edu
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unless otherwise stated.behind these effects are unclear, but may reflect, in part,
the effects of vitamin D on the innate immune response
of the lung.
Prior studies have indicated that vitamin D plays an
important intracrine role in serum monocyte and macro-
phage response to infection [6]. Macrophages, monocytes,
T-cells, and dendritic cells express 1-alpha-hydroxylase
which converts 25-hydroxyvitamin D (25(OH)D) to its
active form 1,25-dihydroxyvitamin D (1,25(OH)D). Macro-
phages constitutively express the vitamin D receptor and
serum macrophages have been shown to enhance innate
immunity by vitamin D regulated production of cathelicidintd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Gerke et al. Multidisciplinary Respiratory Medicine 2014, 9:18 Page 2 of 7
http://www.mrmjournal.com/content/9/1/18in response to mycobacteria [7]. Vitamin D-regulated
human cathelicidin production also promotes autophagy
of the macrophage, an important process in removing
infectious antigens [8].
Despite these reports of the importance of vitamin D
in serum macrophages, there are few data regarding the
specific relationship of the alveolar macrophage to vita-
min D status or supplementation. In this study, the ob-
jective was to determine how vitamin D regulates lung
innate immunity. We performed a double-blind, placebo
controlled, randomized trial in humans to investigate the
effects of vitamin D on alveolar macrophage gene expres-
sion. The hypothesis was that vitamin D supplementation
will affect the gene expression profile of the alveolar macro-
phage in human subjects.
Methods
Trial design
This study was performed as a specific analysis of a
double-blind, parallel-group, randomized controlled
intervention study of the effects vitamin D on alveolar
macrophage gene expression in both smoking and
nonsmoking subjects. The study was approved by the
institutional review board at the University of Iowa
(IRB# 200607708) and written consent was obtained from
all subjects. The study is registered on ClinicalTrials.org
(NCT01967628). An independent data safety monitor-
ing board met regularly to review safety and occur-
rence of adverse events. The study was monitored by
the sponsoring agency to evaluate study progress,
quality of data collection, and adherence to regulatory
and study protocols.
Participants
Subjects were included if they were 18–60 years old and
able to understand and sign a consent form. Subjects
were recruited from the community via advertisements
and word-of-mouth. Subjects were excluded if they had
taken a multivitamin or vitamin D supplement within
the previous three months, were pregnant or breastfeed-
ing, had a vaccination within one month, had a history
of asthma, diabetes, heart disease, allergy to lidocaine, or
any other medical problem that would increase risk of
bronchoscopy (e.g. renal disease or electrolyte imbalance).
Subjects were also excluded if they had a respiratory infec-
tion in the six weeks prior to enrollment, history of pneu-
monia within three years, history of positive tuberculin
skin test, or use of antibiotics for any purpose within six
weeks of enrollment. Subjects were excluded if they were
taking any prescription medication except for hormonal
birth control, topical medications for mild skin ailments,
selected antidepressants, levothyroxine, as needed acid re-
flux treatment, as needed over-the-counter antihistamine,
or as needed sleep aids.Intervention
After obtaining informed consent, included subjects under-
went randomization to 1000 international units (IU) per
day of cholecalciferol (Vitamin D3) by oral capsule or a
matching placebo capsule for a three-month period of time
(total dose of 90,000 IU). Prior to treatment, each subject
underwent bronchoscopy with bronchoalveolar lavage
to obtain alveolar macrophages. After three months of
treatment with vitamin D or placebo, each subject then
underwent a second bronchoscopy to obtain alveolar mac-
rophages. Bronchoscopies were performed by a pulmonary
physician in standard fashion using a flexible bronchoscope
(model P160 or P180; Olympus) at the University of Iowa
Hospitals and Clinics (Iowa City, Iowa, USA) between May
2008 and July 2010. Subjects were premedicated with either
morphine 10 milligrams (mg) or meperidine 12.5-25 mg
intramuscularly and atropine 0.6 mg intramuscularly prior
to bronchoscopy. Subjects did have the option of foregoing
premedication. Subjects were then administered topical
anesthesia with 2%-4% lidocaine to numb the airway. Under
standard clinical monitoring, the bronchoscope was intro-
duced trans-nasally or transorally into the right lung. To
collect alveolar macrophages, bronchoalveolar lavage was
performed by instilling five aliquots of 20 milliliters of
sterile normal saline into three segments of the lung and
suctioning back into a trap container. Blood was drawn at
each subject visit prior to bronchoscopy to assess for levels
of 25(OH)D, 1,25(OH)D, parathyroid hormone, calcium,
and creatinine. Women of childbearing potential under-
went urine pregnancy screen prior to each bronchoscopy.
Outcomes
The primary outcome was to assess the effects of vitamin D
supplementation on differential gene expression as de-
termined by microarray analysis of alveolar macrophage
messenger RNA (mRNA). Gene expression was compared
between placebo and treatment groups, as well as a paired
analysis pre- and post-supplementation within the group
treated with vitamin D.
Randomization
Subjects were randomized on a 1:1 basis to Vitamin D3
or a matching placebo capsule by a computer generated
randomization list provided by the data coordinating
center. Each study participant was assigned to a study
product allocation number by the data coordinating
center after study consent. Study participants, clinical
research team, sponsoring agency, and data analysts were
blinded to intervention assignment. The vitamin D and
placebo were identical in appearance.
Statistical analysis: clinical data
All clinical data analysis was conducted using SAS version
9.1.3 (SAS Institute, Inc., Cary, North Carolina). To confirm
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the two sample T-test was used to compare whether there
were differences in two treatment groups for all the con-
tinuous demographic variables. The T-test was also used to
investigate between-group differences in clinical outcomes.
The Fisher’s Exact test was used for gender to test whether
the assignment was balanced.
Preparation of RNA and microarray analysis
RNA preparation, quality analysis, and microarray analysis
were done as previously described [9]. Measurements
of genome-wide macrophage mRNA expression were
conducted using the GeneChip Human Exon 1.0 ST Arrays
(Affymetrix). Microarray data were analyzed with Partek
Genomics Suite, version 6.5, software (Partek, St. Louis,
MO, USA). The data were assessed for quality and sub-
jected to robust multi-array averaging normalization.
The method of statistical analysis was the paired T-test
(before vitamin D supplementation versus after vitamin
D supplementation in the treated group). A p of 10−5
was considered significant in this analysis. Gene path-
way analysis was conducted using the GoMiner suite
(Genomics and Bioinformatics Group, Bethesda, MD, USA)
of algorithms. The expression data has been deposited in
NCBI Geo repository.
Gene validation and analysis
Three candidate genes, chosen for biological plausibility
and statistical significance, were validated by polymerase
chain reaction (PCR). The genes, CCL8, P2RY10, and
SOX13 were analyzed in samples from subjects whose
serum 25(OH)D levels rose greater than 5 ng/ml. Total
RNA (300 ng) was reverse-transcribed to cDNA using
iScript cDNA Synthesis kit (Bio-Rad). SYBR Green-based
quantitative PCR reactions (BioRad) were performed as
previously described [9]. Specificity of the amplification
was confirmed using melting curve analysis. Expression
levels were defined as a ratio between the threshold cycle
(Ct) values of CCL8, P2RY10, SOX13 and the endogenous
control, HPRT.
Results
Overall distribution of subjects
105 human subjects were enrolled (Figure 1) between
May 2008 and July 2010. The trial was completed after a
predetermined endpoint of time was achieved. After sign-
ing informed consent, seven of the enrolled subjects were
found to have exclusion criteria and were not randomized.
Ninety-eight subjects were randomized to intervention.
Thirteen subjects were terminated early. For the purposes
of this analysis, we excluded 27 subjects who smoked from
the analysis, as smoking has known profound effects
on macrophage gene expression. For the final analysis,
58 subjects were included.Clinical outcomes
Demographics and labs, stratified by treatment group
(Vitamin D versus Placebo), of the 58 subjects who were
analyzed are described in Table 1. There were no differences
in age or lab values between treated and placebo groups, in-
dicating that randomization was effective. There were mar-
ginal overall differences between treatment and placebo
groups in the change of 25(OH)D level (p-value = 0.10) and
parathyroid hormone level (p = 0.05), but no significant
changes in 1,25(OH)D levels or calcium levels (Table 2).
Figure 2 shows the distribution of the change of 25(OH)D
levels by treatment group.
Gene expression
Paired analysis was performed on the group treated with
vitamin D (pre- and post-supplementation) (Table 3). There
were seven genes with P less than 105: Putative P2Y purino-
ceptor 10 (NM_014499), monocyte chemoattractant protein
2 (CCL8/MCP-2)(NM_005623), Homer protein homolog 2
(NM_199330), asparaginyl-tRNAsynthetase 2 (NM_024678),
Ras association (RalGDS/AF-6) domain family member
(NM_014737), SRY (Sex Determining Region Y)-Box 13
(NM_005686), Melanocortin 3 receptor (NM_019888). Only
the monocyte chemoattractant protein 2 (CCL8/MCP-2)
had a fold-change of greater than 1.5. Pathway analysis
showed differentially regulated immune pathways, but all
had a false discovery rate of greater than 0.25 (Table 4).
There were no significant differences in alveolar macrophage
gene expression between treated and placebo groups.
Gene validation
To validate the array data we chose three genes based on
plausibility and significance (two upward trending, and one
downward trending) in the paired analysis of the treated
group. We found that with all three genes, the individual
assays (n = 11) replicated the change trends found in the
array data (Figure 3).
Safety and adverse events
There were fourteen total adverse events reported among
eight of the subjects: nine events in placebo group and five
events in the vitamin D treated group. There were no serious
adverse events or procedure-related adverse events among
the 58 subjects. Indigestion after taking the study drug was
the only study-related adverse event in a patient taking vita-
min D. Adverse events determined to be unrelated to the
study included epididymitis, urinary tract infection, increased
worry, irritability and/or depression, complication of an un-
related medical procedure during the study period, abnormal
vaginal bleeding, uterine cramping, and head injury.
Compliance
In the treatment group, thirteen subjects (46%) completed
full therapy, and eleven (39%) of subjects had residual
Figure 1 Subjects enrollment.
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number of missed capsules was 6.5 capsules (range 1–15),
equating to an average total missed dose of 6500 IU. Four
treated subjects did not bring back their pill bottles for
compliance analysis. In the placebo group, thirteen subjectsTable 1 Comparison of patient’s characteristics by






Age (years) 26.3 25.6 0.72
Baseline 25(OH)D* level (ng/ml) 32.9 30.9 0.56
Baseline 1,25(OH)D† level (pg/ml) 49.3 51.2 0.67
Baseline parathyroid hormone (pg/ml) 34.9 36.8 0.57
Baseline calcium level (mg/dl) 9.2 9.1 0.47
Male gender (%) 36.7% 63.3% 0.20
*25-hydroxyvitamin D.
†1,25-hydroxyvitamin D.completed full therapy (43%) and sixteen subjects (53%)
had missed doses. The average number of missed capsules
was 8.8 (range 1–30). One placebo subject did not bring
back the pill bottle for analysis.
Discussion
In this study, we used microarray technology to determine
gene expression differences in human subjects treated with






Change in 25(OH)D* level (ng/ml) 0.20 4.43 0.10
Change in 1,25(OH)D† level (pg/ml) 1.13 −3.71 0.30
Change in parathyroid hormone (pg/ml) 7.83 1.21 0.05


























Figure 2 Treatment effect for 25-hydroxyvitamin D (25(OH)D)
levels by treatment group (vitamin D versus placebo) (p = 0.10).
Table 3 The thirty most differentially regulated genes
in subjects treated with vitamin D supplementation
(pre- versus post-supplementation)
RefSeq Gene symbol P Fold change
NM_014499 P2RY10 1.45E-05 1.30
NM_005623 CCL8 1.99E-05 1.51
NM_199330 HOMER2 2.11E-05 1.25
NM_024678 NARS2 2.16E-05 1.23
NM_014737 RASSF2 2.86E-05 1.15
NM_005686 SOX13 8.37E-05 −1.12
NM_019888 MC3R 9.95E-05 1.41
NM_173079 RUNDC1 0.00017 1.97
NM_000693 ALDH1A3 0.00019 1.22
NM_024839 RPP21 0.00022 −1.35
NM_198562 C3orf62 0.00022 −1.21
NM_005164 ABCD2 0.00027 1.16
NM_017649 CNNM2 0.00028 1.19
NM_014240 LIMD1 0.00028 −1.18
NM_004123 GIP 0.00030 1.27
NM_001040653 ZXDC 0.00031 −1.20
NM_001100389 TMEM192 0.00033 −1.14
NM_207111 RNF216 0.00033 −1.18
NM_014033 METTL7A 0.00035 1.18
NM_014751 MTSS1 0.00036 1.14
NM_002145 HOXB2 0.00037 1.20
NM_144669 GLT1D1 0.00037 1.20
AF258559 LYRM4 0.00040 −1.79
NM_002258 KLRB1 0.00046 1.28
NM_145178 ATOH7 0.00048 1.22
NM_006545 NPRL2 0.00048 −1.11
NM_015550 OSBPL3 0.00048 −1.14
NM_003239 TGFB3 0.00051 1.18
NM_001719 BMP7 0.00054 1.17
AY204749 NCRNA00114 0.00055 1.27
Table 4 Top differentially regulated gene pathways in








Insulin growth factor-1/mTOR pathway 20 0.59 1.41
Calcineurin pathway 18 0.57 1.35
Rac1 pathway 22 0.55 1.32
Interleukin-10 anti-inflammatory pathway 17 0.56 1.30
B-cell receptor pathway 33 0.51 1.28
Cytokine pathway 21 0.53 1.27
Caspase pathway 23 0.52 1.27
*All pathways have false discovery rate of greater than 0.25.
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ences in resting alveolar macrophage gene expression mod-
ulated by vitamin D supplementation. To our knowledge,
this is the first study that shows the effects of vitamin D
supplementation on alveolar macrophage gene expression
in a clinical trial in humans.
The importance of vitamin D in bone health is well-
established and has been the standard by which adequate
serum levels and supplementation have been based.
The effects on the non-classical roles of vitamin D in
autoimmune disease, cancer, and immunity have sparked
intense controversy over the past decade. It is unknown
whether higher recommended daily doses are needed, or
what the ‘normal’ 25(OH)D level should be. In immunity,
the question of whether vitamin D effects are primarily
anti-inflammatory or antimicrobial is unclear, and data re-
garding its effects supporting both innate and adaptive im-
munity exist [10,11]. For innate immunity, vitamin D has
been shown to enhance the immune response to infection
by increasing cathelicidin and phagocytosis in serum mac-
rophages, important mechanisms in fighting infection [7].
Since alveolar macrophages and airway epithelial cells are
able to convert vitamin D to its active form, it is plausible
that this type of antimicrobial action is also present in the
lung [12]. However, to date, randomized controlled tri-
als on whether vitamin D supplementation decreases
the incidence of respiratory infections have been conflicting
in various populations [13-15].
Our strongest upregulated inflammatory gene is mono-
cyte chemoattractant protein 2 (CCL8/MCP-2). CCL8 is




























































Pre Vit D Post Vit DPre Vit D Post Vit D Pre Vit D Post Vit D
Array ratio 
(Post vit D/Pre vit D): 1.51
Array ratio 
(Post vit D/Pre vit D): 1.15
Array ratio 
(Post vit D/Pre vit D): -1.11
Figure 3 Comparison of pre and post supplementation mRNA of candidate genes in subjects treated with vitamin D whose
25-hydroxyvitamin D level rose greater than 5 ng/ml (measured by polymerase chain reaction).
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and basophils via a number of receptors. It is also thought
to be a potent inhibitor of HIV through through its action
on the CCL5 (chemokine ligand 5) [16]. CCL8 has been
found to be elevated in tuberculosis infection and proposed
as a potential biomarker of tuberculous pleural effusions
[17-19]. Prior studies have indicated effects of vitamin D on
suppression of MCP-1 and inflammation, but there have
been no prior reported studies that we are aware showing a
relationship between vitamin D and CCL8/MCP-2 [20,21].
Given the importance of CCL8 in anti-viral and anti-
tuberculous activity, this cytokine warrants further study
in relation to vitamin D and the lung.
There are a number of factors that may have affected
our results towards a less robust gene expression analysis.
First of all, despite good compliance with treatment, the
amount of vitamin D supplementation was not enough to
uniformly raise serum 25(OH)D levels in all of our sub-
jects, and thereby, likely diluted the true effects of vitamin
D. This may be similar to prior study showing no differ-
ence in outcomes in subjects with tuberculosis treated
with vitamin D; however, the treated patients did not show
an increase in their vitamin D levels [22]. In our validation
process, we tested the gene expression of the candidate
genes in the patients who increased their 25(OH)D levels
and were able to show a more pronounced effect. Paired
analysis of the treated group showed more significant
differences in gene expression, as it likely reduced the
baseline subject variability. Another limitation is that
the alveolar macrophages were harvested in steady
state without stimulation by antigens or microbes that
may be needed to promote vitamin D-regulated tran-
scription. Next, our subject population was relatively
young, limiting generalizability to older or elderly pop-
ulations. Lastly, our sample size may have not been
large enough, with high variability within groups, to
provide power to this type of complex whole genome
analysis. Future research is warranted with clinical tri-
als with further refinement of patient groups, increased
sample size, and protocol methods to ensure enoughvitamin D to raise serum vitamin D levels. Given the
number of vitamin D insufficient or deficient people in the
population, research on vitamin D’s effects on immunity
could have important public health implications.
Conclusions
In conclusion, we found small, but potentially important,
differences in gene expression of the resting alveolar
macrophage in human subjects supplemented with vita-
min D. The results of this study, both of the microarray
analysis and the lessons learned in the trial methods, will
help design future studies to evaluate the effects of vitamin
D on lung innate immunity. Future studies need to focus
on the correlation of effects with serum 25(OH)D levels,
the response of activated alveolar macrophages to vitamin
D, and effects related to gender, age, and race.
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